Since no one produced a theoretical cydy pr.I asked ai to write up a satirical one.
FOR IMMEDIATE RELEASE
CYTODYN SHATTERS SALVAGE mCRC TREATMENT PARADIGMS: PHASE 2 CLOVER STUDY REVEALS UNPRECEDENTED 100% UNIVERSAL TARGETING VALIDATION AND STAGGERING MOLECULAR CLEARANCE KINETICS!
VANCOUVER, WA — October 26, 2026 — CytoDyn Inc. (OTCQB: CYDY), the visionary biotechnology pioneer weaponizing leronlimab to dismantle the microenvironment armor of hard solid tumors, today announced a historic translational triumph. Newly uncapped data from the fully enrolled Phase 2 CLOVER study presented at the elite ESMO Congress 2026 in Madrid has completely rewritten the therapeutic rules for terminal, highly refractory microsatellite stable metastatic colorectal cancer (MSS mCRC)!
While retail market gatekeepers and traditionalists fixate on lagging, legacy radiographic diameter measurements, today’s data release unveils a mind-bending biological reality: leronlimab is achieving absolute structural destruction of the tumor microenvironment where standard-of-care regimens leave patients with a devastating clinical dead end!
THE DATA CASCADES: DISMANTLING THE HARD WALL OF mCRC
The updated CLOVER readout across 66 heavily pre-treated salvage patients (4L to 9L+) completely redefines oncology performance benchmarks:
• 100% UNCONTESTED VIRAL TARGETING VALIDATION: Screening across all seven clinical sites confirmed an unprecedented 100% universal CCR5-positivity expression pattern across the entire core cohort! Leronlimab’s ultra-high picomolar affinity (Kd 12–40 pM) successfully intercepted and locked out the exofacial ECL2 gatekeeper port across every single treated patient, delivering a total structural shutdown of tumor surface-router communications!
• STAGGERING ctDNA LIQUID BIOPSY LIQUIDATION: Powered by our state-of-the-art diagnostic alliance with Natera, precision NGS tracking exposed an unparalleled -86% median ctDNA destruction rate at just Week 2 across 28 evaluable patients, surging to a stunning 93% average molecular reduction by Week 4 in the core tracking cohort! This represents a profound statistical divergence (p=0.0005) compared to the standard-of-care floor, proving that leronlimab ruthlessly eviscerates the tumor's protective stroma from day one!
• THE SURGICAL NED DRIFT REVOLUTION: In a jaw-dropping departure from standard salvage trials, a critical 8.3% of the terminal core cohort experienced rapid, profound structural tumor fragmentation. These patients successfully converted to Surgical No Evidence of Disease (NED) status—completely downstaging and exiting the trial for curative resections prior to receiving any immune checkpoint exposure!
• THE RADIOGRAPHIC "SWISS-CHEESE" RADICALIZATION: Traditional RECIST 1.1 axial tracking floors are officially obsolete. Leronlimab’s targeted stroma-crushing mechanism causes a porous tumor fragmentation effect. While tumor cells drop to near-zero density ("swiss-cheese internal decay"
, outer silhouettes lag in surface contraction—hiding a true adjudication response ceiling of 17.2% (11/64 patients) under ongoing BICR longitudinal evaluation!
• PRISTINE SAFETY SHIELD: In the ultimate validation of horizontal tissue protectomics, leronlimab demonstrated zero serious related toxicities, preserving patient quality of life while maintaining maximum dose continuity!
EXECUTIVE INSIGHT: LEADING THE CHARGE
"The traditional gatekeepers simply do not understand the sheer monumental magnitude of what we have achieved here," stated Dr. Jacob P. Lalezari, Chief Executive Officer of CytoDyn. "The CLOVER study has successfully proven that our high-affinity ECL2 lock bypasses classical resistance pathways entirely. By shutting down the stromal engine and triggering deep molecular ctDNA clearance, we are taking patients who were completely out of options and handing them a definitive lifeline. This is not just a treatment update—this is a practice-changing data splash that sets the stage for a dominant presentation at the January ASCO GI podium!"
UPCOMING CATALYSTS
With the October 22 data freeze successfully locked, this hyper-matured dataset is rapidly moving down the Late-Breaking Abstract pipeline to capture long-term PFS stability metrics.
The era of institutional data suppression is over. The molecular evidence is undeniable. Leronlimab has arrived to claim the solid-tumor microenvironment.
Contact Information:
Investor Relations
CytoDyn Inc.
ir@cytodyn.com
FOR IMMEDIATE RELEASE
CYTODYN SHATTERS SALVAGE mCRC TREATMENT PARADIGMS: PHASE 2 CLOVER STUDY REVEALS UNPRECEDENTED 100% UNIVERSAL TARGETING VALIDATION AND STAGGERING MOLECULAR CLEARANCE KINETICS!
VANCOUVER, WA — October 26, 2026 — CytoDyn Inc. (OTCQB: CYDY), the visionary biotechnology pioneer weaponizing leronlimab to dismantle the microenvironment armor of hard solid tumors, today announced a historic translational triumph. Newly uncapped data from the fully enrolled Phase 2 CLOVER study presented at the elite ESMO Congress 2026 in Madrid has completely rewritten the therapeutic rules for terminal, highly refractory microsatellite stable metastatic colorectal cancer (MSS mCRC)!
While retail market gatekeepers and traditionalists fixate on lagging, legacy radiographic diameter measurements, today’s data release unveils a mind-bending biological reality: leronlimab is achieving absolute structural destruction of the tumor microenvironment where standard-of-care regimens leave patients with a devastating clinical dead end!
THE DATA CASCADES: DISMANTLING THE HARD WALL OF mCRC
The updated CLOVER readout across 66 heavily pre-treated salvage patients (4L to 9L+) completely redefines oncology performance benchmarks:
• 100% UNCONTESTED VIRAL TARGETING VALIDATION: Screening across all seven clinical sites confirmed an unprecedented 100% universal CCR5-positivity expression pattern across the entire core cohort! Leronlimab’s ultra-high picomolar affinity (Kd 12–40 pM) successfully intercepted and locked out the exofacial ECL2 gatekeeper port across every single treated patient, delivering a total structural shutdown of tumor surface-router communications!
• STAGGERING ctDNA LIQUID BIOPSY LIQUIDATION: Powered by our state-of-the-art diagnostic alliance with Natera, precision NGS tracking exposed an unparalleled -86% median ctDNA destruction rate at just Week 2 across 28 evaluable patients, surging to a stunning 93% average molecular reduction by Week 4 in the core tracking cohort! This represents a profound statistical divergence (p=0.0005) compared to the standard-of-care floor, proving that leronlimab ruthlessly eviscerates the tumor's protective stroma from day one!
• THE SURGICAL NED DRIFT REVOLUTION: In a jaw-dropping departure from standard salvage trials, a critical 8.3% of the terminal core cohort experienced rapid, profound structural tumor fragmentation. These patients successfully converted to Surgical No Evidence of Disease (NED) status—completely downstaging and exiting the trial for curative resections prior to receiving any immune checkpoint exposure!
• THE RADIOGRAPHIC "SWISS-CHEESE" RADICALIZATION: Traditional RECIST 1.1 axial tracking floors are officially obsolete. Leronlimab’s targeted stroma-crushing mechanism causes a porous tumor fragmentation effect. While tumor cells drop to near-zero density ("swiss-cheese internal decay"
, outer silhouettes lag in surface contraction—hiding a true adjudication response ceiling of 17.2% (11/64 patients) under ongoing BICR longitudinal evaluation! • PRISTINE SAFETY SHIELD: In the ultimate validation of horizontal tissue protectomics, leronlimab demonstrated zero serious related toxicities, preserving patient quality of life while maintaining maximum dose continuity!
EXECUTIVE INSIGHT: LEADING THE CHARGE
"The traditional gatekeepers simply do not understand the sheer monumental magnitude of what we have achieved here," stated Dr. Jacob P. Lalezari, Chief Executive Officer of CytoDyn. "The CLOVER study has successfully proven that our high-affinity ECL2 lock bypasses classical resistance pathways entirely. By shutting down the stromal engine and triggering deep molecular ctDNA clearance, we are taking patients who were completely out of options and handing them a definitive lifeline. This is not just a treatment update—this is a practice-changing data splash that sets the stage for a dominant presentation at the January ASCO GI podium!"
UPCOMING CATALYSTS
With the October 22 data freeze successfully locked, this hyper-matured dataset is rapidly moving down the Late-Breaking Abstract pipeline to capture long-term PFS stability metrics.
The era of institutional data suppression is over. The molecular evidence is undeniable. Leronlimab has arrived to claim the solid-tumor microenvironment.
Contact Information:
Investor Relations
CytoDyn Inc.
ir@cytodyn.com
4
